click enter text
full postview small beat qtr guidanc
modestli higher skyrizi crush
report financi result friday market
open revenu in-lin ep beat small degre
also gave revenu ep guidanc modestli
higher compar us/consensu
stand-out perform newer drug skyrizi psoriasi along
strong guidanc combin sale rinvoq rheumatoid
arthriti anoth newer launch humira continu well despit
partial cannib two product despit competitor
product also compet market abbv leverag
immunolog inflamm categori high across three product
account pro-forma abbv agn revenu
revenu ep estim rise modestli stand-alon
declin onward due faster us humira
eros assumpt base manag commentari
futur us eros trend may look like admittedli anyon guess far
advanc net intermediate-term number look better out-year
number look wors howev pend allergan acquisit
come blunt impact us humira biosimilar
pt rise repres
updat pro-forma ep report financi monday may
revis model pt impli target
multipl stand-alon ep continu valu base
pro-forma abbv agn estim given deal schedul close
bodi report full analysi
addit detail us/eu drug
compani cover see januari issu
monthli controversi report
trade fundament data
upsid target
factset/wolf research price feb
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
friday open
report result in-lin consensu revenu beat ep small degre
gave revenu ep guidanc modestli ahead us/consensu usual
compani also provid specif guidanc
saw share price rise nearli outperform peer group broader market wide margin
overal impress quarter decent howev perform skyrizi psoriasi realli
stood guidanc revenu slightli estim better consensu
ep guidanc higher us/consensu major focal point investor partli
arent mani catalyst focu pipelin full late-stag nme remain on-going
skyrizi rinvoq uptak trend perform brand directli address long-stand bear
case abbv heavi depend humira note even fold us humira still account
pro-forma revenu year biosimilar entri intern biosimilar eros alreadi
underway us doesnt begin manag gave robust set estim
sale two replac product help investor sentiment upon question
also provid commentari expect us humira biosimilar eventu arriv
specif note analyst often model eros curv look like stairstep realiti
may faster up-front eros partli biosimilar seller come market
eros continu beyond moder level total new
softli messag point sinc shortli deal announc compani ask whether
grow impact said earli know model healthi y/i contract
flattish financi thereaft spent fair bit time talk pipelin late-
stage opportun repres indic expans exist brand early-stag pipelin
varieti nme yet pass proof concept guid poc readout
mean hard assess realist drug compani early-stag pipelin
lot option littl abil predict may surviv backdrop major earli
stage compound actual fail somewher along way fold abbv outlook better
find posit neg transact posit side revenue/ep trajectori post-
better even flattish y/i drop acquir collect
product reason valuat neg side doesnt bring much anyth tabl
term nucleu drug compani therefor transact cynic
describ financi engin mere design backfil come hole parent compani
pro-forma price-to-earnings multipl basi stock still cheap rel peer entic especi context
dividend yield littl pipelin light term late-stag nme
 track record good still heavi leverag us humira even pro-forma basi
upper limit price-to-earnings multipl re-rat rate peer perform posit bia
low rel valuat low event risk higher dividend yield note previous
inform stock cover see januari issu
revenu report sale vs consensu
page
ep report non-gaap ep vs consensu
humira sale vs consensu
imbruvica sale vs consensu
hcv sale vs consensu
skyrizi sale vs consensu continu rapid ramp sinc launch
guidanc stand-alon deal closur exhibit
revenu approach oper growth vs consensu
ep vs stand-alone w/o consensu
pipelin materi news compani gave greater clariti variou program develop
early- late-stag
stand-alon revenu increas ep increas
revenu stand-alon estim increas across period
declin around due faster us humira biosimilar eros
assumpt earn stand-alon estim increas
declin
ep compound-annual-growth-rate pro-forma ep compound-annual-growth-rate increas slightli vs prior
well peer averag growth peer average compound-annual-growth-rate
price set use pro-forma estim increas vs prior repres
new pro-forma ep estim impli price-to-earnings
report
page
provid combin abbv agn guidanc deal close nme poc read-out acquisit
drive high sd revenu growth long time remain track close synergi object
remain
ep growth guidanc stand-alon rinvoq skyrizi contribut combin
skyrizi rinvoq expect revenu growth fx minim impact us
intenational current fx hem/onc imbruvica venclexta hcv recal
previous guid annual sale would stabil around creon duodopa
om net inc tax share count flat ep sale growth
cer humira us intenational skyrizi imbruviva op margin
 updat long-term guidanc deal close made final decis yet whether
go beyond
 possibl divest legaci product like compani co want
divest drag overal compani growth doesnt feel realli long tail
 busi perform trend vs first announc transact
synergi guidanc still track perform strong perform first two
quarter track slightli ahead deal model project synergi mention prepar
remark remain comfort target everyth progress plan closur
end
 context ftc unpredict could eyebrow rais azn take back
brazikumab divest first place might ftc question whether competit futur
develop product said deal like divestitur requir compani meet
ftc discuss possibl asset purchas happen case suggest ftc issu
 us humira biosimilar eros expect expect compani continu grow
overal period loe want give guidanc point howev
note consensu model stairstep us biosimilar eros eu experi shown sharper initi
declin follow moder management expect moment us probabl
competitor launch could potenti declin term total compani growth
growth year thereaft readi guid yet
 remicad us sale less sale biosimilar
stair-step exactli comment say differ remicad
page
competitor came time wherea humira us mani thu expect
faster step-down
navitoclax first class product enter myelofibrosi year
 address prior guidanc venclexta imbruvica still track say
remain comfort venclexta see inflect mm one driver remain
 calquenc azn impact imbruvica feel good data packag
imbruvica make difficult competitor overcom breath-of-data standpoint remind
purport point differenti realli materi calquenc take share
cll manag non-coval inhibitor develop mrk arqul
equival data difficult compet space imbruvica play smaller segment
patient product may take share base see today imbruvica side effect
context strength imbruvica efficaci make non-issu realli
skyrizi alreadi annual run rate nearli alreadi establish lead in-play psoriasi share
new switch patient commerci access pariti humira
rinvoq captur in-play market humira cannib low thu far commerci access
also atop derm data come like benefit itch similar pfe commentari abrocitinib
humira continu contribut growth
 previous guid combin sale skyrizi rinvoq still hold abv
say level risk adjust move along may chang could exceed
everyth hit
 averag durat therapi skyrizi rinvoq skyrizi enough experi thu far
expect durat high humira quarterli dose
 rinvoq lighter expect anyth might affect track well didnt
get broad market access januari realli rx driven access program free
product chang
 outlook admit difficulti uptak endometriosi may lead inflect
potenti earli chang long-term project
page
call sq levo/carbo deliveri system less invas significantli expand pd
patient popul pivot data launch highlight steroid/tnf could
deliv transform efficaci see data year could becom platform across diseas like
ra/ibd/sl also call jak/btk variou program io t-cell bispecif
advanc multipl myeloma
 earli stage compound excit point onc side
submit regulatori applic ovarian/breast
page
exhibit show compani report actual result vs estim consensu
exhibit abbvi result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit abbvi guidanc vs wr estim old new
page
newoldnewtot op growth interest tax guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement agn incom statement product revenu
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper revenu earli phase total
exhibit wr balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
